Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

recruiting125%
unknown125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruiting

Dupilumab Therapy for EGIDs

NCT07257835
completedphase_2

Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization

NCT02270255
unknownphase_2

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

NCT01684956
completedphase_1

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

NCT00642538

Clinical Trials (4)

Showing 4 of 4 trials
NCT07257835

Dupilumab Therapy for EGIDs

Recruiting
NCT02270255Phase 2

Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization

Completed
NCT01684956Phase 2

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

Unknown
NCT00642538Phase 1

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4